Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor α subunits, by targeting HIF α for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF α subunit sequences which may modulate this interaction.
1. An isolated polypeptide which consists of from 8 to 7 amino acids, said polypeptide being capable of forming a complex with VHL, whose sequence is found in region 549-652 of human HIF-1 α (SEQ ID NO: 18).
2. The isolated polypeptide of claim 1 wherein said sequence is found in region 549-572 of human HIF-1 α (SEQ ID NO: 18).
3. The polypeptide of claim 1 fused to a membrane translocation sequence.
4. The polypeptide of claim 1 for use in a method of inhibiting the interaction of an HIF α subunit with VHL.
5. An isolated polypeptide which consists of from 8 to 27 amino acids, said polypeptide being capable of forming a complex with VHL, and characterized by the presence of a sequence selected from the group consisting of:
LAPYIPMD; SEQ ID NO: 1;
LAPYISMD; SEQ ID NO: 2;
LLPYIPMD; SEQ ID NO: 3;
LVPYIPMD; SEQ ID NO: 4;
IAPYIPMD; SEQ ID NO: 5;
IAPYIPME; SEQ ID NO: 6; and
LVPYISMD; SEQ ID NO: 7.
6. An isolated polypeptide which consists of from 19 to 27 amino acids, said polypeptide being capable of forming a complex with VHL, wherein said polypeptide comprises the sequence DLDLEMLAPYIPMDDDFQL (SEQ ID NO: 8); and variants thereof in which there are from 1 to 4 substitutions.
7. The polypeptide of claim 5 fused to a membrane translocation sequence.
8. An isolated polypeptide comprising multiple copies of peptides, wherein said copies of peptides are independently chosen from:
peptides which consist of from 8 to 27 amino acids, said peptides being capable of forming a complex with VHL, whose sequence is found in region 549-652 of human HIF-1 α (SEQ ID NO: 18), and
peptides which consist of from 8 to 27 amino acids, said peptides being capable of forming a complex with VHL, and characterized by the presence of a sequence selected from the group consisting of:
LAPYIPMD; SEQ ID NO: 1;
LAPYISMD; SEQ ID NO: 2;
LLPYIPMD; SEQ ID NO: 3;
LVPYIPMD; SEQ ID NO: 4;
IAPYIPMD; SEQ ID NO: 5;
IAPYIPME; SEQ ID NO: 6; and
LVPYISMD; SEQ ID NO: 7.